[go: up one dir, main page]

GB202317050D0 - Disease modifying anti-rheumatic drug combination therapies - Google Patents

Disease modifying anti-rheumatic drug combination therapies

Info

Publication number
GB202317050D0
GB202317050D0 GBGB2317050.9A GB202317050A GB202317050D0 GB 202317050 D0 GB202317050 D0 GB 202317050D0 GB 202317050 A GB202317050 A GB 202317050A GB 202317050 D0 GB202317050 D0 GB 202317050D0
Authority
GB
United Kingdom
Prior art keywords
combination therapies
drug combination
disease modifying
modifying anti
rheumatic drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2317050.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istesso 2 Ltd
Original Assignee
Istesso 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istesso 2 Ltd filed Critical Istesso 2 Ltd
Priority to GBGB2317050.9A priority Critical patent/GB202317050D0/en
Publication of GB202317050D0 publication Critical patent/GB202317050D0/en
Priority to PCT/EP2024/081568 priority patent/WO2025099187A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB2317050.9A 2023-11-07 2023-11-07 Disease modifying anti-rheumatic drug combination therapies Ceased GB202317050D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2317050.9A GB202317050D0 (en) 2023-11-07 2023-11-07 Disease modifying anti-rheumatic drug combination therapies
PCT/EP2024/081568 WO2025099187A1 (en) 2023-11-07 2024-11-07 Disease modifying anti-rheumatic drug combination therapies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2317050.9A GB202317050D0 (en) 2023-11-07 2023-11-07 Disease modifying anti-rheumatic drug combination therapies

Publications (1)

Publication Number Publication Date
GB202317050D0 true GB202317050D0 (en) 2023-12-20

Family

ID=89164826

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2317050.9A Ceased GB202317050D0 (en) 2023-11-07 2023-11-07 Disease modifying anti-rheumatic drug combination therapies

Country Status (2)

Country Link
GB (1) GB202317050D0 (en)
WO (1) WO2025099187A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4647071A1 (en) * 2024-05-10 2025-11-12 Istesso Therapeutics Limited Mitochondrial complex i modulator for use in the treatment of arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001067103A1 (en) 2000-03-06 2001-09-13 Bioseek, Inc. Function homology screening
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
KR101501375B1 (en) * 2012-09-21 2015-03-10 가톨릭대학교 산학협력단 Composition for preventing or treating inflammatory bowel disease comprising metformin as an active ingredient
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
EP3262028B1 (en) 2014-12-17 2021-10-27 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
GB201905520D0 (en) 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
GB202308547D0 (en) * 2023-06-08 2023-07-26 Istesso 2 Ltd Tnf inhibitor combination therapies
GB202309515D0 (en) * 2023-06-23 2023-08-09 Istesso 2 Ltd JAK inhibitor and IL-6 inhibitor combination therapies

Also Published As

Publication number Publication date
WO2025099187A1 (en) 2025-05-15

Similar Documents

Publication Publication Date Title
EP3954395A4 (en) Pharmaceutical composition for muscle disease treatment
EP3316928A4 (en) SELF-INJECTORS FOR ADMINISTERING A MEDICINE WITHIN A PRE-FILLED SYRINGE
BR112017027843A2 (en) pharmaceutical formulations comprising tenofovir and emtricitabine
EP3607963A4 (en) THERAPEUTIC DRUG FOR FIBROUS DISEASES
EP3801069A4 (en) Combination therapy for pi3k-associated disease or disorder
IL278813A (en) Gene therapy for alzheimer's disease
PH12014502107B1 (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
ZA202205344B (en) Gene therapy for alzheimer's disease
IL288266A (en) Gene therapy for alzheimer's disease
GB202317050D0 (en) Disease modifying anti-rheumatic drug combination therapies
EP4006144A4 (en) Therapeutic medicine for fibrosis, inflammation, and/or age-related diseases
GB202017496D0 (en) Determining a clinical outcome for a subject suffering from a macular degenerative disease
EP3998109A4 (en) NOVEL THERAPEUTIC FOR PROTOTHECA DISEASE
CY1122418T1 (en) TREATMENT OF ERYTHROMELALGY
IL276701A (en) Oligonucleotide therapy for wilson disease
SG11202111852TA (en) Therapeutic drug for dyskinesia
IL283721A (en) Formulation for administering a drug through the large intestine
HUE065591T2 (en) Medicament for treating infectious diseases
GB201817469D0 (en) Gene therapy for retinal disease
HUE069327T2 (en) Prophylactic or therapeutic drug for neurodegenerative diseases
IL267716A (en) Drug combination treatments using bone-targeting therapeutics for bone and bone-related disease
IL307803A (en) Pharmaceutical hydronidone formulations for diseases
GB202104611D0 (en) Gene therapy for retinal disease
HK40043272A (en) Therapy-based database model for generating drug libraries
GB202017101D0 (en) Disease software control

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)